L'EM/SFC est une maladie physique chronique dont le trait caractéristique est le malaise post-effort, un effondrement différé déclenché par l'effort. La thérapie par exercices gradués, autrefois standard, a été retirée en 2021.
Le pilier est désormais la gestion de l'énergie (pacing) : apprendre à vivre dans les limites de l'énergie dont on dispose afin de s'effondrer moins souvent. Les soins quotidiens consistent en une gestion régulière des symptômes : sommeil non réparateur, vertiges et accélération du cœur des problèmes orthostatiques, et douleur.
Practice Ranking
Every practice we track for Chronic Fatigue Syndrome (ME/CFS): What the Evidence Supports, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
3 practices · 1 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Pacing: How Staying Within Your Energy Envelope Prevents Crashes in ME/CFS and Long COVID The frontline approach: stay within your energy envelope to avoid post-exertional crashes. Management, not a cure. | Moderate | Self-Directed | – | – | – | |
| 2 | Cognitive Behavioral Therapy: What It Treats, How Strong the Evidence Is, and How to Start Supportive CBT can help some people cope, alongside pacing; it is not a cure and remains contested in the patient community. | Emerging | Self-Directed | Free to $$ | Moderate to Hard | Weeks | |
| 3 | Coenzyme Q10: What the Trials Show for Heart Failure, Migraine, and Statin Muscle Pain Coenzyme Q10 plus NADH lowered exercise heart rate and eased fatigue over 8 weeks in one 80-person trial. | Preliminary | Supplement | $ to $$ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
ME/CFS turns on one feature: post-exertional malaise. Ordinary tiredness has dozens of causes and is covered on the Fatigue page. When the illness begins after a COVID infection, it overlaps with Long COVID.
What It Is
Myalgic encephalomyelitis, also called chronic fatigue syndrome, is a long-term physical illness marked by disabling fatigue that rest does not fix.
One feature sets it apart from ordinary tiredness: post-exertional malaise.
A small physical or mental effort triggers a delayed, disproportionate crash, often a day or two afterward, that can last for days or weeks.
There is no single blood test; a doctor recognizes ME/CFS by its pattern:
- months of fatigue that does not lift with rest,
- the crash after exertion,
- unrefreshing sleep,
- trouble with memory, concentration, or standing upright.
Those same symptoms also point to four treatable conditions: thyroid disease, sleep apnea, anemia, celiac disease. The diagnosis is settled only after each is ruled out, so an early, careful assessment matters.
Severity spans a wide range, and doctors group it in three bands:
- Mild: activity is cut by around half; many keep working or studying by giving up leisure, social life and rest margins, then crash after any overexertion.
- Moderate: most people are housebound, managing daily tasks only in short bursts with rest between.
- Severe and very severe: people are largely or entirely bed-bound, often unable to tolerate light, sound or being moved, and may need help with eating and washing. Trivial-looking exertions can cause a lasting setback. This most severely affected group is often under-recognized.
Many also feel worse upright: light-headed and unsteady, with palpitations that ease on lying down. This overlaps with postural tachycardia syndrome (POTS), one more form of orthostatic intolerance and treatable on its own. ME/CFS affects women more often than men.
How It Works
The crash has a measurable physical basis. On a maximal exercise test repeated on two consecutive days, people with ME/CFS look much like healthy but inactive people on day one. On day two they cannot repeat it, reaching lower oxygen consumption and workload at both peak effort and the anaerobic threshold. Healthy sedentary controls reproduce their day-one results. That day-one-to-day-two drop is a physical marker of post-exertional malaise, and only the two-day test reveals it. It points away from simple deconditioning: the control group was inactive too, yet recovered normally. A classification model detected the two-day drop with 95.1% accuracy.
ME/CFS often begins after an infection, so in many people it is a post-viral illness. COVID made the overlap plain. Among people still severely fatigued six months after a mild or moderate infection, 19 of 42 met the full 2003 Canadian consensus criteria for ME/CFS, post-exertional malaise included. They closely resembled patients whose illness had followed other infections. What triggers it in one person, and the immune and metabolic mechanisms behind the crash, are still being worked out.
What Helps
Pacing comes first. Also called energy management, it means learning where your limit sits and staying under it, so effort does not tip into a crash. Pacing keeps you as active as the illness allows without slipping into all-day bed rest. It does not cure ME/CFS; it lowers how often you crash and makes a fluctuating illness more livable. In patient surveys it is the approach people rate most helpful and least likely to set them back. That is why current guidance builds care around it. A large trial has not yet tested individualized pacing head to head, so for now it rests on patient experience and today's guidance. The PACE trial tested a separate, fixed pacing protocol, which did no better than usual specialist care; it is not the same as day-to-day energy management. The practical core is learning your own early warning signs and stopping before you reach the limit.
The exercise question needs the most care, because getting it wrong has harmed people. For years, graded exercise therapy, a program of steadily increasing activity, was the standard, built on the PACE trial. A Cochrane review still finds a small fatigue benefit on low-to-moderate-certainty evidence. Large patient surveys reported high rates of harm from graded exercise. When PACE was reanalyzed using the study's own original scoring rules, the recovery claims came out far smaller than first reported, and no better than the comparison group. Most trials showing a benefit used broad entry rules that did not require post-exertional malaise. So they may not apply to the people whose effort reliably triggers a crash. Weighing the harm reports against the deflated recovery claims, the 2021 UK national guideline withdrew graded exercise therapy, and it is no longer offered.
Talk therapy and brain-retraining are sometimes sold as treatments for the illness itself. In that same reanalysis, cognitive behavioral therapy did not change the illness, though it helps some people cope. Brain-retraining programs such as DNRS are marketed directly at ME/CFS. These programs are built around nervous-system sensitization, which is real, but no controlled trial has tested the program itself. Any claim that it reverses the illness is unconfirmed, the research to judge it has not been done.
No drug changes the course of ME/CFS. Rituximab, a B-cell-depleting drug, was the most-watched attempt and matched placebo in a well-run 151-patient trial: response rates ran 26.0% on the drug and 35.1% on placebo. That closed off a leading disease-modifying hope, though it speaks only to rituximab and leaves other immune approaches still under study. A small trial of coenzyme Q10 plus NADH is preliminary and industry-affiliated. In one 80-person study it eased fatigue and lowered the heart rate people reached on an exercise test over eight weeks. It did nothing for pain or sleep, and one author was affiliated with a nutrition company. Beyond these, chronic-fatigue supplement protocols and private tests are sold directly to consumers online. Most are unregulated and none has been tested in a controlled trial. That does not prove they do nothing, it means the evidence is not there yet.
Most care is steady, symptom-by-symptom work you largely run yourself, and four pieces matter most:
- Orthostatic intolerance and POTS, one of the more treatable pieces. Options include more fluids and salt where a doctor agrees, compression garments, standing up slowly, and medication a doctor may add.
- Unrefreshing sleep and pain, each treated as a problem in its own right.
- Aids, help at home and adjustments at work or school that suit a changing illness.
- Anything that adds to the load (thyroid disease, sleep apnea, low mood) found and treated.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Energy And Fatigue
Rituximab worked no better than placebo (26.0% vs 35.1% response) in a 151-patient trial
A well-run trial of rituximab, a drug that depletes immune B cells, found it worked no better than placebo for ME/CFS, closing off one of the most-watched attempts at a treatment that changes the disease.
In a randomized, double-blind, placebo-controlled multicenter trial of 151 patients meeting Canadian criteria, rituximab produced an overall response rate of 26.0% versus 35.1% for placebo (difference -9.2 percentage points, 95% CI -23.3 to 5.5), and the groups did not differ in fatigue score over 24 months or on any secondary measure. Serious adverse events occurred in 26% of the rituximab group and 19% of the placebo group. Measured in: 151 adults aged 18 to 65 with ME/CFS by Canadian consensus criteria, ill for 2 to 15 years, at five Norwegian hospitals. This was a well-powered, blinded trial, so the null result is firm for rituximab, but it applies to this one drug and does not rule out other immune approaches under study; the primary outcome was self-reported.
Who this may not transfer to:Both sexes were enrolled with a female majority typical of ME/CFS; the trial did not report sex-stratified response rates.
The study · 1
Fluge et al., B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial · Ann Intern Med 2019;170(9):585-93
Across 8 trials in 1,518 adults, exercise therapy probably eased fatigue a little, on low-to-moderate certainty
Pooled trials found that graded exercise probably lowered fatigue a little compared with doing nothing, but the certainty was low, whether it caused harm was unclear, and most trials did not specifically enroll people with the crash-after-effort pattern.
A Cochrane review of 8 randomized trials in 1,518 adults found that exercise therapy, mostly graded aerobic activity, probably reduced fatigue at the end of treatment compared with passive control, on low-to-moderate certainty evidence. The review judged the effect on serious harms to be uncertain, and most included trials recruited under broad criteria that did not require post-exertional malaise. Measured in: 1,518 adults with a primary diagnosis of chronic fatigue syndrome across 8 randomized controlled trials, using a range of diagnostic criteria. Most trials used broad definitions that did not require post-exertional malaise, so the results may not describe the people for whom exertion reliably triggers a crash; the review flagged uncertainty about harms, and its own publisher has stated it is being updated.
Who this may not transfer to:Trials enrolled both sexes with a female majority typical of ME/CFS cohorts; the review did not report sex-stratified effects.
The study · 1
Larun et al., exercise therapy for chronic fatigue syndrome · Cochrane Database Syst Rev 2019;10:CD003200
Reanalyzed by its own original protocol, PACE's CBT and graded exercise did no better than the comparison group
When the PACE trial data was analyzed the way its own plan had specified, the recovery and improvement numbers for CBT and graded exercise were far lower than first reported and no better than the comparison group, with any small gains limited to how people rated themselves.
A reanalysis of the PACE trial using its own originally specified protocol found that, after correcting for the planned comparisons, CBT and graded exercise did not significantly outperform the control group on overall improvement, and recovery rates were consistently low and did not differ across groups. Significant effects were almost entirely on self-report measures and did not last beyond two years. Measured in: Reanalysis of data from the 641-patient PACE randomized trial (Oxford criteria), using protocol-specified outcomes obtained through a Freedom of Information request. This is a reanalysis of an existing trial, not a new study, and it inherits the original trial's design limits, including a broad case definition and unblinded, self-reported primary outcomes; those same features are why the authors caution that the modest self-report gains could reflect reporting bias.
Who this may not transfer to:The underlying PACE trial enrolled both sexes with a female majority; the reanalysis did not report sex-stratified outcomes.
The study · 1
Wilshire et al., rethinking the treatment of chronic fatigue syndrome: a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT · BMC Psychol 2018;6(1):6
The structured pacing program in PACE did no better than specialist care at 52 weeks
The specific structured pacing program tested in the main trial did no better than usual specialist care, which is a separate question from the day-to-day energy management that patients and current guidance describe as pacing.
In the PACE randomized trial of 641 patients, the formal protocol tested as adaptive pacing therapy, added to specialist medical care, did not improve fatigue or physical function more than specialist medical care alone at 52 weeks. Measured in: 641 adults meeting Oxford criteria for chronic fatigue syndrome, recruited from six UK secondary-care clinics. Adaptive pacing therapy as manualized in this trial is not the same thing as the individualized energy management now called pacing, so this null result speaks to one formal protocol, not to the general approach; the trial also used the broad Oxford definition, which does not require post-exertional malaise.
Who this may not transfer to:Both sexes were enrolled with a female majority; the trial did not report sex-stratified primary outcomes.
The study · 1
White et al., comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial · Lancet 2011;377(9768):823-36
In an 80-person trial, coenzyme Q10 plus NADH lowered exercise heart rate and eased fatigue over 8 weeks
In a small trial, a coenzyme Q10 and NADH supplement lowered the heart rate people hit during an exercise test and eased their sense of fatigue over eight weeks, though it did nothing for pain or sleep.
In an 8-week, randomized, double-blind, placebo-controlled proof-of-concept trial of 80 patients, coenzyme Q10 plus NADH significantly lowered the maximum heart rate reached during a cycle exercise test at week 8 (P=0.022) and reduced perceived fatigue versus placebo (P=0.03). Pain and sleep did not improve. The combination was well tolerated. Measured in: 80 adults with chronic fatigue syndrome in a single-center trial in Barcelona. The trial was small, ran only eight weeks, and its main endpoint was a heart-rate measure during exercise, not day-to-day function, so the finding is preliminary; one author was affiliated with a nutrition company.
Who this may not transfer to:Both sexes were enrolled with a female majority; the trial did not report sex-stratified effects.
The study · 1
Castro-Marrero et al., effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome: a randomized, controlled, double-blind trial · Clin Nutr 2016;35(4):826-34
Measurement And Diagnosis
Environ 0.89 % des personnes souffrent de SFC/EM, les femmes 1.5 à 2 fois plus souvent que les hommes
On estime qu'environ 0.9 personne sur 100 souffre de SFC/EM selon les critères habituels, et les femmes sont touchées environ une fois et demie à deux fois plus souvent que les hommes, bien que ce chiffre varie beaucoup selon la façon dont il est comptabilisé.
Une méta-analyse de 46 études couvrant plus de 1,085,000 personnes a estimé la prévalence du SFC/EM à 0.89 % selon la définition de cas la plus couramment utilisée (CDC-1994), avec une estimation par méta-analyse à effets aléatoires sur toutes les définitions de 0.68 % (IC à 95 % 0.48 à 0.97). Les estimations variaient largement selon la définition de cas et la méthode d'établissement du diagnostic, de 0.09 % par diagnostic médical à 1.14 % par entretien. Les femmes étaient touchées environ 1.5 à 2 fois plus souvent que les hommes. Measured in: More than 1,085,000 participants from community-based surveys and primary care sites across 46 studies published from 1980 to 2018. Les estimations variaient largement selon la définition de cas et la méthode diagnostique utilisée, de sorte qu'aucun chiffre de prévalence unique n'est définitif ; les auteurs notent l'absence d'un test diagnostique objectif comme principale raison de cette dispersion.
Who this may not transfer to:Both sexes were included; the review found women affected about 1.5 to 2 times as often as men across every subgroup analyzed.
The study · 1
Lim et al., systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) · J Transl Med 2020;18(1):100
19 of 42 people with lasting post-COVID fatigue met the full ME/CFS criteria
In a study of people still exhausted six months after a mild or moderate COVID infection, nearly half met the full criteria for ME/CFS, including the crash after exertion, showing that the illness can be triggered by COVID much as it can follow other infections.
In a prospective cohort of 42 people with persistent moderate-to-severe fatigue and exertion intolerance six months after mild-to-moderate COVID-19, 19 met the 2003 Canadian consensus criteria for ME/CFS, including post-exertional malaise. The post-COVID ME/CFS group resembled a matched cohort whose ME/CFS had followed other infections. Measured in: 42 adults (29 women, 13 men, median age 36.5) with persistent post-COVID fatigue, compared with an age- and sex-matched post-infectious non-COVID ME/CFS cohort. What could explain it instead: People who volunteer for a post-COVID fatigue study are selected for severity, so the share meeting ME/CFS criteria here is likely higher than among all people who catch COVID; unmeasured prior health differences could also shape who develops lasting symptoms.. Il s'agit d'une petite cohorte observationnelle issue de la première vague pandémique, de sorte que la proportion de personnes développant un SFC/EM après la COVID ne peut pas en être généralisée ; elle établit que le chevauchement est réel, sans en mesurer la fréquence.
Who this may not transfer to:Both sexes were included (29 women, 13 men); the cohort was too small for reliable sex-stratified analysis.
The study · 1
Kedor et al., a prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity · Nat Commun 2022;13(1):5104
How it works
A second exercise test a day later exposes a drop that sorts ME/CFS from controls with 95.1% accuracy
Les personnes atteintes de SFC/EM ont aussi bien réussi que des personnes en bonne santé mais inactives lors d'un test d'effort le premier jour, mais un jour plus tard leur corps ne pouvait pas le répéter, une chute mesurable qui donne au malaise post-effort un marqueur physique qu'un seul test manquerait.
In a two-day cardiopulmonary exercise test, 51 women with ME/CFS and 10 sedentary control women performed alike on day one, but on day two the ME/CFS group reached significantly lower oxygen consumption and workload at both peak effort and the anaerobic threshold, while controls reproduced their results. A classification model separated the groups with 95.1% accuracy on the second test. A separate study likewise found ME/CFS patients unable to reproduce their peak oxygen uptake on the second day. Measured in: 51 women with ME/CFS and 10 sedentary control women, each completing two maximal exercise tests 24 hours apart. What could explain it instead: Deconditioning from inactivity could in principle lower exercise capacity, but the control group was also sedentary and reproduced their day-one results, which points away from deconditioning alone as the explanation for the day-two drop.. Only patients well enough to complete two maximal exercise tests were included, so this cannot describe the more severely affected, and the control group was small. It documents a physiological pattern, not establishing a cause of the illness.
Who this may not transfer to:The Snell cohort was all women; the companion study by Keller included men and women and found the same failure to reproduce peak oxygen uptake on the second day, so the pattern is not thought to be specific to women.
The studies · 2
Snell et al., discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome · Phys Ther 2013;93(11):1484-92
Keller et al., inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment · J Transl Med 2014;12:104
A caution on exercise
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Graded exercise worsened symptoms for 54% to 74% of patients surveyed, while pacing helped 44% to 82%
Across a primary survey of 1,428 patients and comparison surveys totaling 16,665 more, graded exercise therapy was followed by a worsening of symptoms in 54% to 74% of respondents. Cognitive behavioral therapy helped a small share (8% to 35%). Pacing was the most favored approach, with the lowest rate of reported harm and the highest reported benefit (44% to 82%). Survey data captures what patients report after the fact, not a controlled comparison, so it cannot measure effect size precisely; even so, the size and consistency of the harm signal for graded exercise across independent surveys is what current guidance weighed.Geraghty et al., ME/CFS patients' reports of symptom changes following CBT, GET and pacing treatments: analysis of a primary survey compared with secondary surveys
Do not push through the fatigue
The instinct to exercise your way back to fitness is the one that backfires here. In ME/CFS, structured graded exercise made a large share of people worse, and current guidance no longer recommends it as a treatment. Pacing to avoid post-exertional crashes is the approach that holds up. The advice that helps ordinary deconditioning is the opposite of what helps here.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to Get Checked
When to See Someone
Most of living with ME/CFS is steady, day-to-day energy management. A few situations call for a professional. One comes first: a doctor should make this diagnosis after ruling out other causes. These are the signs to get seen about:
- A first assessment: months of these symptoms need a doctor to rule out the treatable causes above before settling on ME/CFS
- Fatigue alongside unexplained weight loss, a fever that will not settle, drenching night sweats, or a new lump, which points toward a cause that needs looking into promptly(seek urgent care)
- A steep, lasting deterioration, or very severe illness where someone cannot take in enough food or fluid, which needs prompt medical help(seek urgent care)
- Fainting, chest pain, or a new or severe pounding or racing heart, which should be assessed(seek urgent care)
- New or worsening neurological symptoms: weakness in a limb, loss of coordination, double vision or trouble speaking, not part of ME/CFS, and needing review(seek urgent care)
- Thoughts of harming yourself or ending your life: contact your local emergency number or crisis line now, and tell someone nearby(seek urgent care)
- Low mood or anxiety: common alongside a disabling illness, and deserving care in its own right
- Any plan to start or stop a prescribed medicine, those changes belong with whoever prescribed it
ME/CFS is a serious illness, and much of what steadies it is self-directed, once a doctor has confirmed the diagnosis and ruled out other causes.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine reads a long, depleting illness like this as a vacuity pattern, the body drained of its resources. It centers on the Spleen, held responsible for making qi from food, and the Kidney. These patterns come from a system used to steady depleted people for well over a thousand years. Not everything that helps a fatigued person shows up in a trial. The tradition holds back too. A depleted person is not given strong draining, purging or stimulating methods; those deepen the exhaustion. The idea that vigorous exercise can restore a depleted person runs against the same caution that modern pacing teaches. The herb choice follows the pattern, so a formula that suits one person can be wrong for the next. Any herbs belong with a qualified practitioner.
Heavy, tired limbs, poor appetite, loose stools, bloating after eating, and a foggy head that worsens with effort. The classical direction is to strengthen the Spleen and build qi gently, so the person is not pushed past what they can hold.
A deep, bone-level exhaustion, low back and knee weakness, feeling cold, poor stamina and low drive. The tradition sees the Kidney as the root of reserve energy, and this pattern points to supporting it slowly.
The picture that often follows a viral illness: low-grade feverishness or night sweats, a dry throat, restless unrefreshing sleep, and a crash after exertion. The direction is to clear what lingers while rebuilding qi and yin, and to avoid overtreating a person who is already depleted.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.